Jeffrey S. Berns, M.D., F.A.C.P., F.A.S.N.
ASSociate Chief, Renal Division
Director, Renal Fellowship Program
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
Undergraduate: Indiana University, Bloomington, IN
Medical: Case Western Reserve University, Cleveland, OH
Institution: University Hospitals of Cleveland, Cleveland, OH
Institution: Yale University, New Haven, CT
Board Certification: Internal Medicine, Nephrology
My research interests have primarily focused on the management of anemia in patients with chronic kidney disease and in hemodialysis patients. Another particular area of interest is drug dosing in patients with reduced kidney function.
Clinical and Other Interests:
General clinical nephrology, glomerular diseases, ICU nephrology and continuous renal replacement therapies, chronic kidney disease, hypertension. I am Co-editor of the Dialysis Section of UpToDate and actively involved as Course Director in teaching nephrology to 2nd year medical students.
Berns JS, Fishbane S, Elzein H, Lynn RI, DeOreo PB, Tharpe DL, Meisels IS: The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodialysis International Vol. 9: 255-263, 2005.
Fishbane S, Berns JS: Hemoglobin cycling in hemodialyis patients treated with recombinant human erythropoietin. Kidney International Vol. 68: 1337-1343, 2005.
Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI: Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney International Vol. 68: 2323-2330, 2005.
Berns JS: Disorders of Magnesium Homeostasis (Chapter 14) Primer on Kidney Diseases (National Kidney Foundation), 4th edition. A. Greenberg (eds.). Elsevier; Philadelphia, PA, Page: 131-135, 2005.
Berns JS: Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Seminars in Dialysis Vol. 18: 22-29, 2005.
Berns JS, Mosenkis A: Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. Hemodialysis International Vol. 9: 7-22, 2005.
Berns, JS: Summary and Comment: Frequency of sit-down patient care rounds, attainment of clinical performance targets, hospitalization, and mortality in hemodialysis patients. Plantinga LC, Fink NE, Jaar BG, Sadler JH, Coresh J, Klag MJ, Levey AS, Powe NR. J Am Soc Nephrol 2004; 15:3144-3153. Seminars in Dialysis Vol. 18: 258-260, 2005.
Berns JS, Fishbane S: Hemoglobin variability:random fluctuation, epiphenomenon, or phenomenon? Seminars in Dialysis Vol. 19: 257-259, 2006.
Berns JS, Kasbekar N: Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clinical Journal of the American Society of Nephrology Vol. 1: 117-129, 2006.
Warburton K, Berns JS: Primary and secondary prevention of cardiovascular disease as patients transition from stage 4-5 CKD to dialysis. Seminars in Dialysis Vol. 16: 17-20, 2006.
Warburton K, Berns JS (Guest Editors): How should medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis? Seminars in Dialysis Vol. 16: 8-24, 2006.
Sonawane S, Kasbekar N, Berns JS: The safety of heparins in end-stage renal disease. Seminars in Dialysis Vol. 19: 305-310, 2006.